Avalo Therapeutics, Inc. (NASDAQ:AVTX) Stock Rated "Moderate Buy" by Sell-Side Analysts

Key Points

• Analysts rate Avalo Therapeutics a “Moderate Buy”: 11 of 14 analysts recommend buying, while two rate it hold and one sell; the average 12-month price target is $36.82.
• Avalo reported a quarterly loss of $0.34 per share, narrower than analysts’ expected loss of $0.59 per share.
• AVTX traded at $7.76, below its 50- and 200-day moving averages and closer to its 52-week low of $6.53 than its high of $24.27. Insiders sold 23,258 shares over the past 90 days.

Shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the fourteen ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eleven have assigned a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $36.82.

A number of research firms have issued reports on AVTX. Cantor Fitzgerald reissued an "overweight" rating on shares of Avalo Therapeutics in a research report on Wednesday, September 16th. Oppenheimer set a $16.00 price objective on Avalo Therapeutics in a report on Monday, October 26th. HC Wainwright downgraded Avalo Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, October 23rd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Avalo Therapeutics in a research note on Wednesday, November 4th. Finally, Wall Street Zen upgraded Avalo Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, November 7th.

Insider Activity

In other news, CFO Christopher Sullivan sold 12,394 shares of Avalo Therapeutics stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $16.33, for a total transaction of $202,394.02. Following the sale, the chief financial officer owned 39,900 shares in the company, valued at $651,567. This trade represents a 23.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 23,258 shares of company stock valued at $395,434 in the last ninety days. 4.46% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Avalo Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Nantahala Capital Management LLC lifted its position in shares of Avalo Therapeutics by 15.0% in the 3rd quarter. Nantahala Capital Management LLC now owns 2,142,308 shares of the company's stock worth $32,842,000 after buying an additional 280,058 shares during the last quarter. Braidwell LP bought a new stake in shares of Avalo Therapeutics during the 2nd quarter valued at about $30,107,000. Affinity Asset Advisors LLC raised its stake in Avalo Therapeutics by 27.6% during the first quarter. Affinity Asset Advisors LLC now owns 1,340,840 shares of the company's stock worth $20,019,000 after acquiring an additional 289,786 shares during the period. Seven Fleet Capital Management LP raised its stake in Avalo Therapeutics by 34.3% during the second quarter. Seven Fleet Capital Management LP now owns 770,765 shares of the company's stock worth $14,244,000 after acquiring an additional 196,882 shares during the period. Finally, Bank of America Corp DE raised its stake in Avalo Therapeutics by 3.5% during the first quarter. Bank of America Corp DE now owns 643,000 shares of the company's stock worth $9,600,000 after acquiring an additional 21,650 shares during the period. Institutional investors own 87.06% of the company's stock.

Avalo Therapeutics Stock Performance

AVTX stock traded up $0.06 during midday trading on Friday, hitting $7.76. 974,092 shares of the stock were exchanged, compared to its average volume of 3,339,771. The stock's 50-day moving average price is $12.33 and its 200-day moving average price is $15.64. The stock has a market cap of $448.68 million, a price-to-earnings ratio of -3.08 and a beta of 0.75. Avalo Therapeutics has a fifty-two week low of $6.53 and a fifty-two week high of $24.27.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.25. Research analysts anticipate that Avalo Therapeutics will post -2.52 EPS for the current year.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. The company does not have marketed products and is centered on advancing drug candidates through clinical development. Its lead candidate, AVTX-009, is a monoclonal antibody that targets interleukin-1 beta (IL-1β), an inflammatory signaling protein. Avalo is developing the therapy for hidradenitis suppurativa, a chronic inflammatory skin disease, and has described potential applications in other inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.